Keros Therapeutics, Inc. Announces Executive Changes
August 02, 2021 at 02:03 pm
Share
On August 2, 2021, Keros Therapeutics, Inc. announced that Simon Cooper, M.B.B.S., has been appointed to serve as the Company’s Chief Medical Officer, effective as of August 2, 2021. Dr. Cooper is succeeding Claudia Ordonez, M.D., who departed from the Chief Medical Officer position effective July 30, 2021 (the “Separation Date”). Dr. Ordonez will provide consulting services to the Company until September 15, 2021. As consideration for these consulting services, the Company will pay Dr. Ordonez a fixed fee of $5,000 and agreed to amend the outstanding stock option award agreements granted to her under the Company’s 2017 Stock Incentive Plan, as amended, and the Company's 2020 Equity Incentive Plan, as applicable, to extend the post-termination exercise period to six months for those options that would otherwise expire three months after the Separation Date. Dr. Cooper, age 52, is joining the Company after most recently serving as the Senior Vice President, Chief Medical Officer of Kadmon Holdings, Inc.
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. Its second product candidate, KER-012, is being developed for the treatment of pulmonary arterial hypertension, or PAH, and for the treatment of cardiovascular disorders. Its third product candidate, KER-065, is being developed for the treatment of obesity and for the treatment of neuromuscular diseases. KER-050 is designed to raise red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-B family of proteins to promote hematopoiesis.
KEROS THERAPEUTICS, INC. 
